Cutaneous toxicity / skin toxicity
- (2026): Yanagawa T+, Gan To Kagaku Ryoho (Japanese) 53(1), 25-30 (73 cases)
- (2024): Saito Y+, In Vivo 38(5), 2390-2398 (77 cases)
- (2023): Saito Y+, Support Care Cancer 31(8), 50461% (risk factors)
Adverse reactions attributed to entire drug class 'Epidermal growth factor receptor (EGFR) monoclonal antibody'
Please login to view adverse reactions.
